Strong efficacy and cardiovascular benefits should allow Novo to continue growing sales of GLP-1 therapies in diabetes. Ozempic and Rybelsus helped Novo gain share over Eli Lilly's once-weekly ...

As consumers drop pounds, beauty and wellness brands are dropping products in hopes of cashing in on the rise of weight-loss drugs.

The top-line outcomes from SUPREME-01 are anticipated between the fourth quarter of 2026 and the first quarter of 2027.

Caliway receives US FDA clearance to proceed with SUPREME-01 phase 3 study of CBL-514 for reducing abdominal subcutaneous fat: New Taipei City Tuesday, July 29, 2025, 14:00 Hrs [I ...

Experts say supplement companies have tried to capitalize on the GLP-1 craze, putting the phrase in their product names, ...

Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

Explore the potential of GLP-1 receptor agonists for rheumatoid arthritis. Learn about their safety, benefits, and what to consider before starting these medications.

There's been plenty of buzz about this class of drug, following publication of a high-profile trial this year. How much do we ...

Detailed price information for Lexaria Bioscience Corp (LEXX-Q) from The Globe and Mail including charting and trades.

Researchers found that tirzepatide, a medication primarily used for treating type 2 diabetes and weight loss, reduced body ...

GLP-1 drugs like Ozempic have already become a game-changer for obesity and diabetes. But new research shows they may also ...

GLP-1 drugs have been compared to the discovery of penicillin, which changed the course of medicine by treating several ...